Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Pre-exposure prophylaxis against HIV infection

Kenneth H Mayer, MD
Douglas Krakower, MD
Section Editor
John G Bartlett, MD
Deputy Editor
Jennifer Mitty, MD, MPH


Up to two million new HIV infections occur yearly worldwide. As there is no effective vaccine to prevent HIV transmission, behavioral and biomedical HIV prevention strategies are needed to reduce HIV acquisition [1,2]. For HIV-uninfected patients, pre-exposure prophylaxis (PrEP) using antiretroviral medications is an evidence-based way to prevent new infections among those at greatest risk.

This topic will review how to identify and manage appropriate candidates for PrEP. A discussion of other strategies to prevent HIV infection, including the use of antiretroviral therapy for HIV-infected patients, post-exposure prophylaxis for HIV-uninfected patients, and male circumcision are discussed elsewhere. (See "HIV infection: Risk factors and prevention strategies" and "Management of nonoccupational exposures to HIV and hepatitis B and C in adults" and "Prevention of sexually transmitted infections", section on 'Male circumcision' and "Management of healthcare personnel exposed to HIV".)


For HIV-uninfected patients who are at high risk for acquiring HIV, and are committed to medication adherence, pre-exposure prophylaxis (PrEP) using tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) can reduce the risk of HIV transmission by more than 90 percent [3]. However, the efficacy of this strategy requires patients' ongoing commitment to adherence. (See 'Efficacy of oral pre-exposure prophylaxis' below and 'Medication adherence' below.)

To determine who should receive PrEP, clinicians should assess the potential benefits and risks of therapy:

Clinicians should obtain a detailed sexual and drug use history to determine if the patient is at high risk of HIV acquisition, and therefore, likely to benefit from PrEP. (See 'Assessing risk of HIV acquisition' below and 'Candidates for pre-exposure prophylaxis' below.)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Dec 2016. | This topic last updated: Mon Jan 09 00:00:00 GMT 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014; 384:258.
  2. Jones A, Cremin I, Abdullah F, et al. Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention. Lancet 2014; 384:272.
  3. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4:151ra125.
  4. http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf (Accessed on May 19, 2014).
  5. Marrazzo JM, del Rio C, Holtgrave DR, et al. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312:390.
  6. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. http://apps.who.int/iris/bitstream/10665/128048/1/9789241507431_eng.pdf?ua=1 (Accessed on September 29, 2014).
  7. Mayer KH, Krakower DS, Boswell SL. Antiretroviral Preexposure Prophylaxis: Opportunities and Challenges for Primary Care Physicians. JAMA 2016; 315:867.
  8. Sullivan PS, Salazar L, Buchbinder S, Sanchez TH. Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. AIDS 2009; 23:1153.
  9. Smith DK, Pan Y, Rose CE, et al. A Brief Screening Tool to Assess the Risk of Contracting HIV Infection Among Active Injection Drug Users. J Addict Med 2015; 9:226.
  10. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587.
  11. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399.
  12. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423.
  13. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411.
  14. Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013; 64:79.
  15. Mugwanya KK, Wyatt C, Celum C, et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med 2015; 175:246.
  16. Gandhi M, Glidden DV, Liu A, et al. Higher cumulative TFV/FTC levels in PrEP associated with decline in renal function. Presented at the Conference on Retroviruses and Opportunistic Infections 2016.
  17. Solomon MM, Schechter M, Liu AY, et al. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. J Acquir Immune Defic Syndr 2016; 71:281.
  18. Mulligan K, Glidden DV, Anderson PL, et al. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis 2015; 61:572.
  19. Grant R, Mulligan K, McMahan V, et al. Recovery of bone mineral density after stopping oral HIV pre-exposure prophylaxis. Presented at the Conference on Retroviruses and Opportunistic Infections 2016.
  20. Mulligan K, Rutledge B, Kapogiannis BG, et al. Bone changes in young men ages 18-22 enrolled in a pre-exposure prophylaxis safety and demonstration study using tenofovir disoproxil fumarate/emtricitabine. Antiviral Therapy 2015; Suppl 1:A21.
  21. Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA 2014; 312:362.
  22. World Health Organization. WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection. http://apps.who.int/iris/bitstream/10665/197906/1/WHO_HIV_2015.48_eng.pdf?ua=1 (Accessed on December 05, 2016).
  23. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm?s_cid=mm6003a1_w (Accessed on January 28, 2011).
  24. Seifert SM, Glidden DV, Meditz AL, et al. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis 2015; 60:804.
  25. Anderson PL, Meditz A, Zheng JH. Cellular pharmacology of TFV and FTC in blood, rectal, and cervical cells from HIV- volunteers. Presented at the Conference on Retroviruses and Opportunistic Infections 2012.
  26. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385:2606.
  27. Massud V, Mitchell J, Babusis D. Chemoprophylaxis with oral FTC/TAF protects macaques from rectal SHIV Infection. resented at the Conference on Retroviruses and Opportunistic Infections, Boston MA, February 22-25, 2016. Abstract# 107.
  28. Garrett K, Cottrell ML, Prince HM. Concentrations of TFV and TFVdp in female mucosal tissues after a single dose of TAF. Presented at the Conference on Retroviruses and Opportunistic Infections, Boston MA, February 22-25, 2016. Abstract# 102LB.
  29. Krakower DS, Mayer KH. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Drugs 2015; 75:243.
  30. Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis 2014; 59 Suppl 1:S55.
  31. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014; 14:820.
  32. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372:509.
  33. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168.
  34. Rees H, Delany-Moretlwe S, Lombard C et al, FACTS 001 Phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. Presented at presented at the Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 2015.
  35. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 2014; 66:340.
  36. Cottrell ML, Yang KH, Prince HM, et al. A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis 2016; 214:55.
  37. Lehman DA, Baeten JM, McCoy CO, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis 2015; 211:1211.
  38. Knox DC, Tan DH, Harrigan R, et al. Multiclass resistant HIV infection despite high adherence to PrEP. Presented at the Conference on Retroviruses and Opportunistic Infections, Boston MA, February 22-25, 2016. Abstract# 169aLB.
  39. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009; 48:806.
  40. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008; 22:1829.
  41. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 2012; 156:541.
  42. Mitchell KM, Lépine A, Terris-Prestholt F, et al. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. AIDS 2015; 29:2035.
  43. Alistar SS, Grant PM, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med 2014; 12:46.
  44. Bernard CL, Brandeau ML, Humphreys K, et al. Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Ann Intern Med 2016.
  45. Myers JE, Sepkowitz KA. A pill for HIV prevention: déjà vu all over again? Clin Infect Dis 2013; 56:1604.
  46. Horberg M, Raymond B. Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance. Am J Prev Med 2013; 44:S125.
  47. Bekker L, Hughes, J, Amico R, et al. A phase II, randomized, open-label, pharmacokinetic and behavioral study of the ise of intermittent oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (PrEP). Presented at the Conference on Retroviruses and Opportunistic Infections, Seattle, Washington 2015.
  48. Molina JM, Capitant C, Spire B, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med 2015; 373:2237.
  49. Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med 2016; 375:2121.
  50. Nel A, van Niekerk N, Kapiga S, et al. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. N Engl J Med 2016; 375:2133.
  51. Solomon MM, Lama JR, Glidden DV, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS 2014; 28:851.
  52. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387:53.
  53. Volk JE, Marcus JL, Phengrasamy T, et al. No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis 2015; 61:1601.
  54. Cohen S, Vittinghoff E, Philip SS. Quarterly STI screening optimizes STI detection among PrEP users in the Demo Project. Presented at the Conference on Retroviruses and Opportunistic Infections, Boston MA, February 22-25, 2016. Abstract# 877.
  55. Mujugira A, Thomas K, Celum C, et al. HIV-1 transmission risk persists during the first 6 months of antiretroviral therapy. Presented at the 22st Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 23-26, 2015. Abstract #989.
  56. Baeten J, Heffron R, Kidoguchi L, et al. Near elimination of HIV transmission in a demonstration project of PrEP and ART. Presented at the 22st Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 23-26, 2015. Abstract #24.
  57. Ping LH, Jabara CB, Rodrigo AG, et al. HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study. PLoS One 2013; 8:e71557.
  58. Deutsch MB, Glidden DV, Sevelius J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV 2015; 2:e512.
  59. Mayer KH, Krakower D. Antiretroviral medication and HIV prevention: new steps forward and new questions. Ann Intern Med 2012; 156:312.
  60. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4.
  61. Stephenson J. Study halted: no benefit seen from antiretroviral pill in preventing HIV in women. JAMA 2011; 305:1952.
  62. Van Damme L, Corneli A, Ahmed K, et a and the FEM-PrEP Study Groupl. The FEM-PrEP Trial of Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) among African Women. Presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 5-8, 2012. Abstract #32LB.
  63. Dai JY, Hendrix CW, Richardson BA, et al. Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. J Infect Dis 2016; 213:335.
  64. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083.
  65. Karim SS. HIV pre-exposure prophylaxis in injecting drug users. Lancet 2013; 381:2060.
  66. Celum C, Morrow RA, Donnell D, et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med 2014; 161:11.
  67. Tan D. Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females. Int J Womens Health 2012; 4:341.
  68. Marcus JL, Glidden DV, McMahan V, et al. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One 2014; 9:e91513.
  69. Herold BC, Chen BA, Salata RA, et al. Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. Clin Infect Dis 2016; 62:375.
  70. MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women, November 2011. http://www.mtnstopshiv.org/node/3909 (Accessed on June 06, 2012).